Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Other Working Capital Changes (2018 - 2025)

10x Genomics (TXG) has disclosed Other Working Capital Changes for 8 consecutive years, with -$9.0 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes fell 17649.02% to -$9.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$10.3 million through Dec 2025, down 642.35% year-over-year, with the annual reading at -$10.3 million for FY2025, 642.35% down from the prior year.
  • Other Working Capital Changes hit -$9.0 million in Q4 2025 for 10x Genomics, down from $3.6 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $5.5 million in Q3 2021 to a low of -$9.0 million in Q4 2025.
  • Historically, Other Working Capital Changes has averaged -$948450.0 across 5 years, with a median of -$840500.0 in 2022.
  • Biggest YoY gain for Other Working Capital Changes was 1381.27% in 2025; the steepest drop was 17649.02% in 2025.
  • Year by year, Other Working Capital Changes stood at -$168000.0 in 2021, then crashed by 3113.69% to -$5.4 million in 2022, then surged by 48.01% to -$2.8 million in 2023, then soared by 101.82% to $51000.0 in 2024, then tumbled by 17649.02% to -$9.0 million in 2025.
  • Business Quant data shows Other Working Capital Changes for TXG at -$9.0 million in Q4 2025, $3.6 million in Q3 2025, and -$2.4 million in Q2 2025.